A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment

Trial Profile

A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Tedizolid (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Trius Therapeutics
  • Most Recent Events

    • 11 Sep 2012 Interim results reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)
    • 07 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top